向基化酶10A破坏瘤微环境中的MAPK信号通路,释放抗瘤免疫力
bioRxiv : the preprint server for biology
|March 11, 2026
概括
一种新的PDE10A抑制剂ADT-030通过增强抗瘤免疫力和破坏癌细胞信号传递,有效抑制瘤生长. 它的有效性依赖于T细胞和树突细胞,这表明一种有前途的免疫治疗方法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 固酶10A (PDE10A) 在人类癌症中过度表达.
- 抑制PDE10A显示出抗瘤作用,但其机制和免疫影响尚不清楚.
研究的目的:
- 为了研究ADT-030的抗瘤疗效和免疫影响,这是一种新的PDE10A抑制剂.
主要方法:
- 在小鼠瘤细胞系中测试了ADT-030的细胞毒性,并在同基因小鼠模型中抑制瘤生长.
- 评估了ADT-030在免疫缺陷小鼠和CD8+T细胞枯竭后的疗效.
- 评估ADT-030对免疫细胞死亡,树突细胞成熟和免疫细胞群 (例如MDSC) 的影响.
- 分析了瘤细胞和MDSC中的MAPK信号通路变化.
主要成果:
- 在多个模型中,ADT-030表现出强大的细胞毒性和口服生物可用性,抑制瘤生长.
- 疗效取决于宿主免疫力,特别是CD8+ T细胞和Batf3表达树突细胞.
- ADT-030诱导了免疫细胞死亡,促进了DC成熟,与抗PD-1疗法协同作用,并减少了髓质衍生抑制细胞 (MDSC).
- ADT-030破坏了瘤细胞和MDSC中的MAPK信号传递,诱导了亡.
结论:
- 通过ADT-030抑制PDE10A是一种有前途的癌症治疗策略.
- ADT-030通过直接的抗瘤作用和调节瘤免疫微环境来抑制瘤的进展.
- ADT-030重新塑造瘤免疫格局,以增强抗瘤免疫力.
相关概念视频
Interactions Between Signaling Pathways
7.7K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K
MAPK Signaling Cascades
9.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression
1.6K
1.6K
Microtubule Associated Proteins (MAPs)
6.2K
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
6.2K
PI3K/mTOR/AKT Signaling Pathway
6.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.1K


